Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study.

ABSTRACT:

Background

The γ-aminobutyric acid type B-receptor agonist lesogaberan (AZD3355) has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite proton pump inhibitor (PPI) therapy (partial responders). This study aimed to explore the dose-response effect of lesogaberan on reflux episodes in partial responders.

Methods

In this randomized, single-centre, double-blind, crossover, placebo-controlled study, partial responders taking optimised PPI therapy were given 30, 90, 120 and 240 mg doses of lesogaberan. Each dose was given twice (12 h apart) during a 24-h period, during which impedance-pH measurements were taken.

Results

Twenty-five patients were included in the efficacy analysis and 27 in the safety analysis. The effect of lesoga

SUBMITTER: Miner PB 

PROVIDER: S-EPMC4289246 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature